{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:45:40Z","timestamp":1761540340872},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2002,2,27]],"date-time":"2002-02-27T00:00:00Z","timestamp":1014768000000},"content-version":"vor","delay-in-days":667,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2000,5]]},"abstract":"<jats:p>The development of an inhibitor to transfused factor VIII (FVIII) is a serious treatment\u2010related problem in haemophiliac children. The management of patients with high titre FVIII inhibitors is difficult, and immune tolerance induction (ITI) is the only method available for the eradication of these inhibitors. The results of the ITI regimen used at the Children\u2019s Hospital of Michigan Haemophilia Treatment Center are described and discussed. ITI was attempted in 14 children with severe haemophilia A (13 high responders, one low responder), with daily doses of FVIII alone. FVIII dosage was chosen according to the patient\u2019s historical peak inhibitor titre. ITI included three phases; induction phase, dose reduction phase and maintenance phase. During the first phase, the starting dose was 50 or 100\u2003U\u2003kg<jats:sup>\u20131<\/jats:sup>\u2003d<jats:sup>\u20131<\/jats:sup>; during the second phase the FVIII dosage was reduced gradually to 25\u2003U\u2003kg<jats:sup>\u20131<\/jats:sup> every other day according to the inhibitor titre, FVIII recovery and\/or half\u2010life study. In the third (maintenance) phase, the children received either prophylactic therapy or episodic therapy for 12\u2003months. The inhibitor elimination was defined as the time taken to achieve a negative inhibitor assay with no anamnestic response and normal FVIII recovery and\/or normal half\u2010life. Immune tolerance was achieved in 11 of 14 patients (79%) patients within a median time of 6\u2003months; two children are still on therapy, three failed ITI. We observed either failure or prolongation of immune tolerance if the historical peak titre or the maximum titre during ITI was\u2003&gt;200 BU. The success rate of our low dose ITI regimen is not different from that reported by other investigators and the inhibitor elimination time is similar to some of the studies reported previously.<\/jats:p>","DOI":"10.1046\/j.1365-2516.2000.00379.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:00:44Z","timestamp":1047423644000},"page":"150-157","source":"Crossref","is-referenced-by-count":43,"title":["Immune tolerance induction in the treatment of paediatric haemophilia A patients with factor VIII inhibitors"],"prefix":"10.1111","volume":"6","author":[{"given":"A.","family":"Unuvar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Warrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Lusher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,2,27]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1055\/s-0038-1657604","article-title":"Factor VIII inhibitors","volume":"78","author":"Gilles JGG","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1996.tb01341.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90874-3"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830470312"},{"key":"e_1_2_7_6_2","first-page":"A1","article-title":"Experiences with recombinant factor VIII products: development of inhibitors and immune tolerance therapy","volume":"76","author":"Scharrer I","year":"1998","journal-title":"Ann Hematol"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197407252910402"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198008213030803"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198109243051301"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.5.1135.1135"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656122"},{"key":"e_1_2_7_12_2","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/archinte.1989.00390060103022","article-title":"The use of porcine factor VIII concentrate (Hyate: C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience","volume":"149","author":"Brettler DB","year":"1989","journal-title":"Arch Intern Med"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.5.882.882"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90259-0"},{"key":"e_1_2_7_15_2","first-page":"124","article-title":"Clinical experience with recombinant factor VIIa","volume":"26","author":"Lusher JM","year":"1996","journal-title":"Hemostasis"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1981.tb02687.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V58.1.38.38"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)90871-6"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1996.tb01349.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)91593-B"},{"key":"e_1_2_7_21_2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1055\/s-0037-1614251","article-title":"Comparison of high responder inhibitor frequency in recent studies of previously untreated patients with hemophilia A","volume":"79","author":"Ehrlich HJ","year":"1998","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_22_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/17843286.1991.11718201","article-title":"Epidemic of factor VIII inhibitors linked to factor VIII\u2010P","volume":"46","author":"Schwarzinger I","year":"1991","journal-title":"Acta Clin Belg"},{"key":"e_1_2_7_23_2","first-page":"590","article-title":"FVIII inhibitors on a SD treated and pasteurized concentrate associated with specific batches and batch characteristics","volume":"77","author":"Rosendaal FR","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_24_2","first-page":"181","article-title":"Induced immunotolerance in factor VIII inhibitor patients","volume":"150","author":"Brackmann HH","year":"1984","journal-title":"Prog Clin Biol Res"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1661062"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198804143181503"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1986.tb04122.x"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199221000-00013"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1996.tb01346.x"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1996.tb01347.x"},{"key":"e_1_2_7_31_2","first-page":"16","article-title":"Immunoadsorption for removal of inhibitors: update on treatments in Malm\u00f6\u2010Lund between","volume":"1998","author":"Freiburghaus C","year":"1980","journal-title":"And 1995 Haemophilia"},{"key":"e_1_2_7_32_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1988.03720010043038","article-title":"Induction of immune tolerance to factor VII in hemophiliacs with inhibitors","volume":"259","author":"Ewing NP","year":"1988","journal-title":"JAMA"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.3.983.983"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1996.tb01348.x"},{"key":"e_1_2_7_35_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-0038-1648828","article-title":"Immune tolerance in hemophilia\u2010principal results from the international registry","volume":"72","author":"Mariani G","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_36_2","first-page":"156a","article-title":"Analysis of the North American immune tolerance registry (NAITR) 1993\u201397 current practice implications","volume":"90","author":"DiMichele DM","year":"1997","journal-title":"Blood"},{"key":"e_1_2_7_37_2","first-page":"782","article-title":"Variables that might affect the outcome of immune tolerance therapy in haemophiliacs with factor VIII inhibitors","volume":"72","author":"Ehrenforth S","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1995.tb00036.x"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1997.00117.x"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.2000.00379.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.2000.00379.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2516.2000.00379.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T11:52:12Z","timestamp":1698580332000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2516.2000.00379.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["10.1046\/j.1365-2516.2000.00379.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2516.2000.00379.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}